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Context: First-generation somatostatin receptor ligands (fg-SRLs) represent the mainstay of 
medical therapy for acromegaly, but they provide biochemical control of disease in only a subset 
of patients. Various pretreatment biomarkers might affect biochemical response to fg-SRLs.
Objective: To identify clinical predictors of the biochemical response to fg-SRLs monotherapy 
defined as biochemical response (insulin-like growth factor (IGF)-1 ≤ 1.3 × ULN (upper limit 
of normal)), partial response (>20% relative IGF-1 reduction without normalization), and 
nonresponse (≤20% relative IGF-1 reduction), and IGF-1 reduction.
Design: Retrospective multicenter study.
Setting: Eight participating European centers.
Methods: We performed a meta-analysis of participant data from 2 cohorts (Rotterdam and 
Liège acromegaly survey, 622 out of 3520 patients). Multivariable regression models were used 
to identify predictors of biochemical response to fg-SRL monotherapy.
Results: Lower IGF-1 concentration at baseline (odds ratio (OR) = 0.82, 95% confidence interval 
(CI) 0.72–0.95 IGF-1 ULN, P = .0073) and lower bodyweight (OR = 0.99, 95% CI 0.98–0.99 kg, 
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error; SST2, somatostatin receptor subtype 2; ULN, upper limit of normal.
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P = .038) were associated with biochemical response. Higher IGF-1 concentration at baseline 
(OR = 1.40, (1.19–1.65) IGF-1 ULN, P ≤ .0001), the presence of type 2 diabetes (oral medication 
OR = 2.48, (1.43–4.29), P = .0013; insulin therapy OR = 2.65, (1.02–6.70), P = .045), and higher 
bodyweight (OR = 1.02, (1.01–1.04) kg, P = .0023) were associated with achieving partial 
response. Younger patients at diagnosis are more likely to achieve nonresponse (OR = 0.96, 
(0.94–0.99) year, P = .0070). Baseline IGF-1 and growth hormone concentration at diagnosis 
were associated with absolute IGF-1 reduction (β = 0.90, standard error (SE) = 0.02, P ≤ .0001 and 
β  = 0.002, SE = 0.001, P = .014, respectively).
Conclusion: Baseline IGF-1 concentration was the best predictor of biochemical response to fg-
SRL, followed by bodyweight, while younger patients were more likely to achieve nonresponse. 
(J Clin Endocrinol Metab 105: 1–11, 2020)
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F irst-generation somatostatin receptor ligands (fg-SRLs) represent the mainstay of medical therapy 
for acromegaly (1, 2). Medical treatment is usually indi-
cated for patients for whom trans-sphenoidal surgery is 
not an option or is not curative. Long-acting fg-SRLs act 
mainly by binding and activating somatostatin receptor 
subtype 2 (SST2), which together with SST5 receptor is 
the most frequently expressed SST subtype of growth 
hormone (GH)-secreting pituitary adenomas 3-5). 
Overall, the efficacies of fg-SRLs, such as lanreotide 
autogel (ATG) and octreotide long-acting release (LAR), 
seem to be similar (6), and patients have biochemical re-
sponse rates varying from 25% to 45% 6-9).
Although fg-SRLs can control hormonal 
hypersecretion in GH-secreting pituitary adenomas, 
many patients are at least partially resistant to treatment 
and will be exposed to high GH and insulin-like growth 
factor 1 (IGF-1) concentrations. Excess of serum GH 
and/or IGF-1 leads to cardiovascular, metabolic, and 
musculoskeletal comorbidities, which, in turn, increase 
mortality as a result of cardiovascular, cerebrovascular, 
and respiratory morbidities (10, 11). However, mor-
tality in patients with acromegaly significantly declined 
over time and could be explained by the availability of 
new medical treatment options (11, 12).
Previous studies have reported several clinical pre-
dictors of biochemical response to fg-SRL mono-
therapy, including age at diagnosis, sex, bodyweight, 
height, serum (nadir) GH, and IGF-1 at diagnosis 
and baseline, tumor size, genetic mutations (eg, aryl-
hydrocarbon receptor interacting protein), T2-weighted 
magnetic resonance imaging signal intensity, patho-
logical features (granulation pattern and SSTs receptors 
of the adenoma) and the presence of type 2 diabetes 
(DM; antidiabetic medication use) as well as previous 
treatment modalities (surgery and medical therapy) 
3-5, 13-26). Overall, these studies have used widely 
differing definitions of biochemical response over time 
and varying study entry criteria (de novo, postsurgery, 
or preselected sensitivity to fg-SRLs) (22). Although no 
validated criteria for fg-SRL therapy failure exist, only a 
small minority (<10%) should be considered to be fully 
resistant to fg-SRLs (27). More importantly, previous 
studies have not been able to identify patient-specific 
clinical predictors for different biochemical response 
groups, including partial responders and nonresponders 
to fg-SRL therapy.
Given the importance of biochemical control in acro-
megaly but the lack of studies investigating predictors 
for the different biochemical response groups, we aim to 
identify clinical predictors of the biochemical response 
to initial treatment with the maximum dose of fg-SRLs 
monotherapy for at least 6 months. We categorized pa-
tients into groups by biochemical response (biochem-
ical response, partial response, and nonresponse) and by 
IGF-1 reduction criteria (absolute and relative). These 
prediction models can be used to guide and individu-
alize treatments and could avoid the consequences with 
ineffective treatment with fg-SRLs such as prolonged 
biochemical and metabolic disease.
Patients and Methods
Cohort description
Patients were included from 2 retrospective cohorts: (1) the 
Rotterdam cohort and (2) the Liège Acromegaly Survey (LAS) 
cohort (21, 28, 29). The Rotterdam cohort contains data from 
acromegaly patients using fg-SRL monotherapy collected 
at the outpatient clinic of the Pituitary Center Rotterdam, 
Erasmus University Medical Center in Rotterdam between 
1977 and 2018. The LAS cohort (n = 3194 from 10 cen-
ters) was created using a software tool that enables hospitals 
throughout Europe to include acromegaly patients and report 
patient, biochemical, and tumor characteristics (21). For this 
study, only patients using fg-SRL monotherapy were enrolled 
from an additional 7 European centers. The inclusion period 
was between 1990 and 2018. Patients receiving fg-SRL mono-
therapy could have previously undergone surgery; however, 
patients that had undergone radiotherapy were excluded from 
the study.
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Rotterdam cohort.  Clinical and biochemical data were 
collected from acromegaly patients initially treated with the 
maximum dose of fg-SRL monotherapy (ie, lanreotide ATG 
120 mg or octreotide LAR 30 mg every 28 days) for at least 
6 months. We excluded 26 patients because they were not ini-
tially treated with the maximum dose of fg-SRL monotherapy 
for at least 6 months. We were able to select 326 potential 
patients using fg-SRL monotherapy. We excluded 132 patients 
for 2 reasons: (1) IGF-1 normalization was achieved (defined 
as ≤1.3 × upper limit of normal (ULN)) at baseline (ie, before 
initiating fg-SRL monotherapy, n = 44), and (2) follow-up 
data during SRL monotherapy were missing (n = 88). In total 
(n = 194) patients remained in the cohort. The subjects then 
visited our outpatient clinic between every 16 and 24 weeks. 
At each visit to our outpatient clinic, standard measurements 
were performed including assessments of IGF-1 and GH con-
centrations. From all patients written informed consent was 
obtained prior to inclusion, and the study was approved by 
the Medical Ethics Committee of the Erasmus University 
Medical Center in Rotterdam.
LAS cohort.  Acromegaly patients from the LAS database 
treated with initially the maximum dose of fg-SRL mono-
therapy for at least 6  months were selected. We excluded 
197 patients because they were not initially treated with the 
maximum dose of fg-SRL monotherapy for at least 6 months. 
From the LAS database, we were able to select 590 potential 
patients using fg-SRL monotherapy. We excluded 162 patients 
for 2 reasons: (1) IGF-1 normalization was achieved at base-
line (defined as ≤1.3 × ULN before initiating fg-SRL mono-
therapy, n = 91), and follow-up data during SRL monotherapy 
were missing (n = 71). In total (n = 428) patients remained 
in the cohort. The medical ethics committee from the Liège 
University hospital approved the protocol and was covering 
the other European centers.
Outcome
The primary endpoint was the biochemical response 
to treatment with fg-SRLs classified as (1) biochemical re-
sponse, defined as a normalized IGF-1 (IGF-1 ≤ 1.3 × ULN) 
irrespective of normalized GH (GH ≤ 2.5 µg/L) concentration 
achieved after at least 6 months of treatment; (2) partial resist-
ance, defined as a >20% relative reduction of IGF-1 without 
normalization; and (3) nonresponse, defined as a failure to 
decrease IGF-1 concentration by >20%, which represents the 
intra-assay variability. The primary endpoint was independent 
of GH values. The secondary endpoints were absolute and 
relative IGF-1 reduction (between serum IGF-1 at baseline 
versus lowest IGF-1 during fg-SRL monotherapy).
Blood measurements. In the Rotterdam cohort, total 
IGF-1 and GH concentrations were measured with different 
assays. IGF-1 concentration before and after fg-SRL treat-
ment were analyzed using different assays: Immulite 2000 
assay, a solid-phase, validated enzyme-labelled chemilumin-
escent immunometric assay (DPC Biermann GmbH/Siemens, 
Fernwald, Germany; intra-assay variability of 2-5%, interassay 
variability of 3-7%) and 2 different radioimmunoassays 
(Diagnostic Systems Laboratories, Webster, TX, USA, intra-
assay coefficient of variation (CV) 3.9%, interassay CV 4.2%; 
and Medgenix Diagnostics, Fleurus, Belgium, intra-assay CV 
6.1%, interassay CV 9.9%). GH concentration was initially 
measured by immunoradiometric assay (CIS Bio International, 
Gif-sur-Yvette, France, intra-assay CV 2.8%, inter-assay 
CV 4.4%). Since February 2013, IGF-1 and GH concentra-
tions were analyzed using an immunometric assay (IDS-iSYS, 
Boldon, UK), which is free of interference from pegvisomant. 
Interassay CVs for GH and IGF-1 were <5% (GH; n = 190) 
and (IGF-1; n = 190) in serum-based internal quality control 
measurements over a period of 1 year.
In the LAS cohort, containing acromegaly patients from 7 
European centers, GH and IGF-1 serum measurements were 
assessed locally and consequently performed with different as-
says. In this study, the IGF-1 concentration was chosen to be 
expressed as the ULN of the reference ranges used in the local 
center (the IGF-1 divided by the age- and sex-specific ULN). 
GH concentration was measured as a single random sample 
and expressed as absolute value.
Candidate predictors
Variables that were considered as possible pretreatment 
predictors required to achieve disease control during fg-SRL 
monotherapy were selected based on previous studies (4, 5, 
13-21, 25, 26, 30-33), biological plausibility and availability 
of robust data ascertainment in both cohorts and included: 
age at diagnosis and baseline, sex, bodyweight, height, serum 
(nadir) GH, and IGF-1 at diagnosis and baseline, tumor size 
(microadenoma, macroadenoma, and nonvisible at diagnosis) 
and the presence of type 2 DM at baseline as well as previous 
treatment modalities (surgery and medical therapy with a 
[partial] dopamine agonist). Bodyweight, GH, and IGF-1 con-
centrations were collected between 6 months before and at the 
time of fg-SRL initiation. Other data were collected at baseline 
(as indicated), were fixed data in the patient’s record, or were 
established during the disease process.
Statistical analysis
Data are expressed as median (interquartile range [IQR]). 
Differences between two subgroups were analyzed using an 
unpaired t-test or the Mann-Whitney U test (in case of a 
nonparametric distribution). Nominal variables were ana-
lyzed using Fisher’s exact test. For all regression models, the 
residuals were normally distributed, final models were not 
affected by multicollinearity, and nonlinearity was assessed 
utilizing restricted cubic splines with 3 or 4 knots. We used 
univariable linear regression models to assess the associ-
ation between each candidate predictor and the outcome. 
The decision for linear regression models instead of mul-
tiple models for the identification of predictors was based 
on Akaike information criteria and log-likelihood tests 
comparing multilevel models with random intercepts and/or 
slope per cohort versus standard linear regression correcting 
for cohort. To allow for optimal generalizability of effect es-
timates that predict the outcome, we performed standard 
linear regression correcting for cohort. We selected useful 
predictors using forward selection based on the change in 
regression coefficients and residual explained variability 
of the model, with P  < .20 to keep predictors liberally in 
the model. To cope with (differentially) missing values of 
the candidate predictors, missing data on candidate pre-
dictors were multiple imputed (50 times). The imputation 
model included most candidate predictor variables (missing 
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values Rotterdam/LAS cohort as percentage, bodyweight 
27.8/19.9%; height: 8.3/1.4%; GH at diagnosis 17.5/11.2%; 
tumor size 2.1/5.1%; panhypopituitarism 0/69.6%; age at 
baseline 0/0.5%; GH at baseline 13.9/11.7%) and the out-
come variables. The candidate predictors age at diagnosis, 
gender, IGF-1 (×ULN) at diagnosis and baseline, the pres-
ence of type 2 DM and previous treatment modalities (sur-
gery and medical therapy) had no missing values. There was 
no difference between the original or any of the imputed 
datasets. All analyses were performed in each of the com-
pleted datasets, and final results were pooled using Rubin’s 
rules. We investigated the predictive discriminative ability 
of significant predictors from the multivariable analyses by 
performing receiver-operating-characteristics analysis. A P 
value <0.05 (two-tailed) was used as a cut-off for statis-
tical significance. All statistical analyses were performed 
using Statistical Package of Social Sciences, version 25.0 
for Windows (SPSS) or using R statistical software, version 
3.5.2 (packages foreign, mice, pROC, and rms).
Results
Cohort characteristics
After exclusions, the final study population com-
prised 662 patients (Fig.  1), the characteristics and 
previous treatment modalities of which are depicted 
in Table 1. Patients included in the LAS cohort were 
younger at diagnosis (44.0 vs 49.0  years) and more 
likely to be diagnosed with a macroadenoma (81.5% 
vs 74.2%). Patients from the LAS cohort more often 
underwent surgery and received medical treatment 
(ie, (partial) dopamine agonist therapy) before the 
start of fg-SRL and had a lower baseline IGF-1 con-
centration. In the total cohort the median duration 
of fg-SRL therapy is 132.4 months (IQR 36.4-215.3) 
and 284 (45.7%) patients received fg-SRL as primary 
treatment. Observed biochemical response occurred 
in 80% of patients and a partial or nonsignificant re-
sponse occurred in 13% and 7%, respectively. No sig-
nificant differences were observed in the Rotterdam 
and LAS cohort between excluded and included 
patients.
Univariable predictors of the biochemical response
All univariable analyses of the candidate predictors 
of biochemical response to fg-SRL monotherapy, 
including predictors of IGF-1 reduction, are depicted 
in Table 2.
Figure 1. Flowchart of the selection procedure. IGF-1, insulin-like growth factor 1; fg-SRL, first-generation somatostatin receptor ligand; ULN, 
upper limit of normal.
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Predictors of biochemical response
In multivariable analyses, baseline IGF-1 concentra-
tion and bodyweight were determinants of biochemical 
response (Table 3). A lower IGF-1 concentration at base-
line was associated with a higher chance of achieving bio-
chemical response (OR 0.82, 95% CI 0.72-0.95 IGF-1 
ULN, P = .0073, Table 3). Moreover, a lower bodyweight 
was associated with a higher chance of a biochemical 
response (OR 0.99, 95% CI 0.98-0.99  kg, P = .038, 
Table 3). The combined discriminative ability of IGF-1 
concentration and bodyweight combined to predict bio-
chemical response was adequate (AUC 0.77, 95% CI 
0.72-0.81; all supplementary material and figures are lo-
cated in a digital research materials repository (34)).
Predictors of partial response
In the multivariable analyses, baseline IGF-1 concen-
tration, the presence of type 2 DM and bodyweight were 
determinants of partial response (Table 3). A higher IGF-1 
concentration at baseline was associated with a higher 
chance of achieving partial response (OR 1.40, 95% CI 
1.19-1.65 IGF-1 ULN, P ≤ .0001, Table 3). The presence of 
type 2 DM was associated with a higher chance of a partial 
response (oral medication OR 2.48, 95% CI 1.43–4.29, 
P = .0013; insulin therapy OR 2.65, 95% CI 1.02-6.70, 
P = .045, Table 3). Moreover, a higher bodyweight was as-
sociated with a higher chance of a partial response (OR 
1.02, 95% CI 1.01-1.04 kg, P = .0023, Table 3). The com-
bined discriminative ability of the IGF-1 concentration, the 
presence of type 2 DM and bodyweight to predict partial 
response was good (AUC 0.80, 95% CI 0.76-0.86 (34)).
Predictors of nonresponse
In multivariable analyses, age at diagnosis, surgery, and 
tumor size at diagnosis were determinants of nonresponse 
(Table  3). Younger patients at diagnosis had a higher 
chance of achieving nonresponse (OR 0.96, 95% CI 0.94-
0.99 year, P = .0070, Table 3). Surgery at baseline tended 
to be inversely associated with a higher chance of a non-
response (OR 0.48, 95% CI 0.22-1.05, P = .067, Table 3). 
In other words, nonresponse patients underwent surgery 
less often. In addition, the presence of a macroadenoma (vs 
microadenoma) at baseline tended to be associated with a 
higher chance of a nonresponse but failed to reach sig-
nificance (OR 2.64, 95% CI 0.89-7.84, P = .081, Table 3). 
Age at diagnosis, surgery and tumor size combined had 
Table 1. Cohort demographics and clinical characteristics of the total group, Rotterdam cohort and LAS 
cohort
Total cohort (n = 622) Rotterdam cohort (n = 194) LAS cohort (n = 428)
Age at diagnosis (years) 46.0 (36.0–55.0) 49.0 (39.8–58.0) 44.0 (34.0–53.0)*
Sex (female) 295 (47.4) 95 (49.0) 200 (46.7)
Bodyweight (kg) 82.8 (71.0–96.4) 90.0 (75.2–100.1) 80.0 (70.0–95.0)*
Height (cm) 172.0 (166.0–180.0) 176.0 (168.8–182.3) 172.0 (165.0–179.3)*
Nadir GH at diagnosis (µg/L) 5.8 (2.4–15.3) 4.3 (1.9–10.6) 6.0 (2.5–18.0)*
GH at diagnosis (µg/L) 8.5 (3.9–21.8) 12.2 (5.9–28.3) 7.3 (3.6–19.8)*
IGF-1 at diagnosis (×ULN) 2.7 (2.0–3.6) 2.9 (2.4–4.1) 2.6 (1.9–3.5)*
Tumor size    
 Microadenoma 103 (16.7) 46 (23.7) 57 (13.5)*
 Macroadenoma 493 (80.2) 144 (74.2) 349 (81.5)*
 Nonvisible adenoma 19 (3.1) 4 (2.1) 15 (3.5)
Presence of type 2 DM 227 (36.5) 76 (39.2) 151 (35.3)
 Oral medication 196 (31.5) 66 (34.0) 130 (30.4)
 Insulin therapy 44 (7.1) 10 (5.2) 34 (7.9)
Previous treatment    
 Surgery 205 (33.0) 38 (19.6) 167 (39.0)*
 Surgical reintervention 22 (3.5) 8 (18.6) 14 (8.4)
 Medical treatment 111 (17.8) 12 (6.2) 99 (23.1)*
Panhypopituitarism 44 (7.1) 27 (13.9) 17 (4.0)*
Age at baseline (years) 47.0 (37.0–56.5) 50.0 (40.0–59.0) 46.0 (36.0–55.0)*
GH at baseline (µg/L) 7.6 (3.5–20.1) 8.1 (3.2–21.8) 7.3 (3.6–19.9)
IGF-1 at baseline (x ULN) 2.7 (1.9–3.6) 2.9 (2.2–4.1) 2.6 (1.9–3.5)*
Octreotide LAR 311 (50) 123 (63.4) 188 (43.9)*
Treatment response    
 Biochemical response 498 (80.1) 114 (58.8) 384 (89.7)*
 Partial response 79 (12.7) 50 (25.8) 29 (6.8)*
 Non-response 45 (7.2) 30 (15.5) 15 (3.5)*
Duration fg-SRL therapy (months) 132.4 (36.4–215.3) 17.7 (8.5–66.7) 177.2 (116.7–243.3)*
Data are mean (SD), median (IQR) or n (%). Asterisk represents P = ≤.05 for the comparisons between Rotterdam and LAS cohort and are derived 
from the Student’s t test (continuous variables) and Pearson’s chi-square test (categorical variables).
Abbreviations: IGF-1, insulin-like growth factor 1; fg-SRL, first-generation somatostatin receptor ligand; Octreotide LAR, Octreotide long-acting re-
lease; ULN, upper limit of normal.
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an adequate discriminative ability to predict non-response 
(AUC of 0.78, 95% CI 0.69-0.85 (34)).
Predictors of IGF-1 reduction
Multivariable analyses to predict absolute IGF-1 
reduction detected a positive association for baseline 
IGF-1 concentration (β  =  0.90, SE  =  0.02, P ≤ .0001; 
Fig. 2A and Table 4). A significant inverse association 
was seen between GH concentration at diagnosis and 
absolute IGF-1 reduction (β  =  –0.002, SE  =  0.001, 
P = .014; Fig. 2B and Table 4).
With regards to relative IGF-1 reduction, the 
multivariable analyses include a positive association 
for baseline IGF-1 concentration (β  =  6.24, SE = 0.66, 
Table 3. Multivariable analysis to predict biochemical, partial and non-response
OR 95% CI P value
Biochemical response    
IGF-1 at baseline (×ULN) 0.82 (0.72–0.95) .0073
Bodyweight (kg) 0.99 (0.98–0.99) .0379
Partial response    
IGF-1 at baseline (×ULN) 1.40 (1.19–1.65) <.0001
Type 2 DM and oral medication a 2.48 (1.43–4.29) .0013
Type 2 DM and insulin therapy a 2.65 (1.02–6.70) .0451
Bodyweight (kg) 1.02 (1.01–1.04) .0023
Nonresponse    
Age at diagnosis (years) 0.96 (0.94–0.99) .0070
Surgery at baseline 0.48 (0.22–1.05) .0666
Macroadenomab 2.64 (0.89–7.84) .0814
Nonvisible adenomab <0.01 (<0.01–∞) .9868
DM, diabetes mellitus; IGF-1, insulin-like growth hormone factor 1; SE, standard error; SRL, somatostatin receptor ligand.
aCompared with patients without type 2 DM.
bCompared with patients harboring a microadenoma.
Table 2. Univariable analysis of the predictors of the biochemical response during first-generation SRL 
monotherapy
Biochemical 
response Partial response Nonresponse
Absolute IGF-1 
reduction
Relative 
IGF-1 re-
duction
Age at diagnosis (years) — — Younger* Nonlinear* Nonlinear b
Sex — — — Male* —
Bodyweight (kg) ↓ Bodyweight** ↑ Bodyweight** ↓ Bodyweightb —  
Height (cm) Smaller* Tallerb Tallera Nonlinearb Smaller**
Nadir GH at diagnosis 
(µg/L)
Nonlinear b Nonlinear* — Nonlinear** Nonlinear*
GH at diagnosis (µg/L) ↓ GH* Nonlinear* ↑ GHa Nonlinear** —
IGF-1 at diagnosis (×ULN) ↓ IGF-1*** ↑ IGF-1*** — ↑ IGF-1*** ↑ IGF-1***
Tumor size      
 Microadenoma — — — — —
 Macroadenoma — — Macroadenomab Macroadenomab —
 Nonvisible adenoma — - — — —
Presence of type 2 DM      
 Oral medication — Yesb — — —
 Insulin therapy — Yesb — — —
Previous treatment      
 Surgery Yes** Yes*** No* No** Yesb
 Surgical reintervention — — — — —
 Medical treatment Yes** Yes*** Nob No** —
Panhypopituitarism No** Yes* Yes** — No**
Age at baseline (years) — Older* Younger* — —
GH at baseline (µg/L) Nonlineara Nonlinearb — ↓ GH** Non-
linear**
IGF-1 at baseline (×ULN) ↓ IGF-1*** ↑ IGF-1*** — ↑ IGF-1*** ↑ IGF-1***
Octreotide LAR — — — — —
Abbreviations: IGF-1, insulin-like growth factor 1; SRL, somatostatin receptor ligand; octreotide LAR, octreotide long-acting release; ULN, upper limit 
of normal.
*P < 0.05,**P < 0.01,***P < .0001.
aBorderline significance at P < .07.
bTrend towards significance at P < .20.
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P ≤ .0001; Fig.  2C and Table  4). In addition, height 
was inversely associated with relative IGF-1 reduction 
(β = –0.1912, SE = 0.0860, P = .027; Fig. 2D and Table 4).
Discussion
This is the first large cohort study to focus on 
identifying clinical predictors of the biochemical re-
sponse to treatment with fg-SRLs by categorizing pa-
tients into groups by response (biochemical response, 
Figure 2. Predictors of IGF-1 reduction. Association between absolute IGF-1 reduction and (A) IGF-1 (×ULN) before start fg-SRL therapy and (B) 
GH concentration at diagnosis. Association between relative IGF-1 reduction and (C) IGF-1 (× ULN) and (D) height before start fg-SRL therapy. The 
grey shade represents the 95% confidence interval of the predicted mean. IGF-1, insulin-like growth factor 1; fg-SRL, first-generation somatostatin 
receptor ligand; ULN, upper limit of normal.
Table 4. Multivariable analysis to predict IGF-1 
reduction
β SE P value
Absolute IGF-1 reduction    
IGF-1 at baseline (×ULN) .90 0.02 <.0001
GH at diagnosis (µg/L) –.002 0.001 .0136
Relative IGF-1 reduction    
IGF-1 at baseline (×ULN) 6.24 0.66 <.0001
Height (cm) –.19 0.09 .0266
Abbreviations: IGF-1, insulin-like growth hormone factor 1; SE, stand-
ard error.
Copyedited by: OUP
D
ow
nloaded from
 https://academ
ic.oup.com
/jcem
/article-abstract/105/9/dgaa387/5863389 by Erasm
us U
niversiteit R
otterdam
 user on 04 August 2020
8  Coopmans et al  Predict SRL response in acromegaly J Clin Endocrinol Metab, September 2020, 105(9):1–11
partial response, and nonresponse) and by IGF-1 re-
duction criteria (absolute and relative). The main 
findings of this study are that (1) baseline IGF-1 con-
centration, bodyweight, and the presence of type 2 DM 
can contribute to distinguishing complete biochemical 
from partial response and (2) that nonresponse during 
fg-SRLs occurred more in patients that were younger 
at diagnosis and tended to harbor larger tumors and 
underwent surgery less often.
In our study, baseline IGF-1 concentration was the 
best predictor of fg-SRL treatment response. A  lower 
IGF-1 concentration at baseline was associated with 
a higher chance of a complete biochemical response, 
while a higher IGF-1 concentration was associated with 
a higher risk of only partial response and higher IGF-1 
(absolute and relative) reduction to fg-SRLs. Previously 
it has been identified that lower circulating IGF-1 and 
GH levels correspond with better biochemical response 
to fg-SRLs (4, 21, 35). Thus, lower baseline IGF-1 con-
centrations could identify patients that will achieve 
biochemical control, while higher baseline IGF-1 con-
centrations could identify those that will achieve partial 
responses while at the same time having a greater ab-
solute and relative reduction in circulating IGF-1 levels. 
While the latter seems counterintuitive, a greater reduc-
tion even if IGF-1 levels will not decrease below the 
set threshold is still of clinical value in the multimodel 
therapy setting.
We observed that a lower bodyweight was associ-
ated with a higher chance of biochemical control, while 
a higher bodyweight was associated with partial re-
sponse to fg-SRLs. This finding is in accordance with 
previous findings from the somutaline depot for acro-
megaly (SODA) registry (13), which identified that pa-
tients with a lower BMI (BMI < 30  kg/m2) tended to 
have better biochemical control of IGF-1 than patients 
with a higher BMI (BMI ≥ 30 kg/m2) after 24 months of 
fg-SRL therapy.
The presence of concomitant type 2 DM, besides 
baseline IGF-1 concentration and bodyweight, is a 
pretreatment predictor of partial response to fg-SRL 
monotherapy, is also expected. The SODA study (13), 
the same study as mentioned before, showed that after 
24 months of fg-SRL therapy, normalization of IGF-1 
concentration was achieved less frequently in diabetic 
patients. In a previous study of the LAS database, a 
significant relationship between glucose levels and 
IGF-1 at baseline was shown for acromegaly patients, 
even in the absence of type 2 DM (21). Overall, the 
prevalence of insulin sensitivity alterations has been 
found to correlate with higher BMI in patients with 
acromegaly as observed in the general population (36). 
Taking into account that type 2 DM patients likely 
had higher bodyweight at enrollment, both findings 
may be explained by the presence of hyperinsulinemia. 
Hyperinsulinemia may counteract possible SRL-
induced pituitary-independent mechanisms of bio-
chemical control by enhancing the synthesis of IGF-1 
through upregulation of hepatic GH receptors (37, 
38). Combined with the fact that fg-SRL therapy may 
impair glucose metabolism, largely owing to inhibition 
of insulin leading to further increase of glucose secre-
tion (39, 40), type 2 DM patients might benefit from 
initial therapy with pegvisomant instead of fg-SRLs.
Age at diagnosis appears to be the most important 
determinant of achieving nonresponse during fg-SRL 
therapy, likely reflecting (indirectly) the exposure to 
high circulating levels of GH and IGF-1 (18, 21, 23, 
28, 41). This observation confirms and builds upon 
previous studies (21, 42) proposing age at diagnosis to 
be a clinical marker of tumor size and aggressiveness. 
Younger patients (aged <40 years) tend to have larger 
and potentially harbor more aggressive tumors than 
older patients; the reason for this is unknown, although 
the increased prevalence of genetic mutations like AIP 
in younger patients with acromegaly–gigantism with 
fg-SRL resistance may play a role (25, 26).
Knowing that larger tumors secrete more GH, while 
older patients generally have lower GH concentrations 
at diagnosis (18, 21, 28), it becomes apparent why 
older patients have been shown to be more sensitive to 
fg-SRLs therapy (18). Subsequent, surgical total tumor 
resection or debulking decreases the basal GH secretion, 
and increases the likelihood of achieving biochemical 
disease control with fg-SRLs. This observation is con-
sistent with long-term trials (20, 43, 44) and our data 
that show a better biochemical control of IGF-1 with 
fg-SRLs after surgery.
A strength of our study is the relatively large number 
of patients in which the biochemical responses to 
fg-SRL treatment were systematically investigated, 
while remaining to be treated with a single agent, with 
a stable high dose for a long period of treatment (ie, 
exceeding the median period of 12 months) when com-
pared with previous literature (27). The LAS data-
base provides some specific advantages in that it is not 
limited to a national dataset nor does it deal with pa-
tients managed with only a single treatment modality, 
and, therefore, may better reflect the general population 
of acromegaly patients and overcome selection bias. In 
our study, we utilize a more liberal definition of bio-
chemical response (defined as IGF-1 ≤ 1.3 × ULN). To 
overcome the limitation of a cutoff validity, we con-
firmed our data by using the cutoff of ≤1.2 × ULN in 
the multivariable analyses, which did not affect the ef-
fect estimates of the final models. The main limitations 
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of our study lie in the retrospective nature of this study. 
Due to the retrospective collection of data on IGF-1 
concentration during fg-SRL treatment, performed on 
patients followed-up for at least 6 months, a selection 
bias cannot be ruled out. It is conceivable that patients 
unresponsive to fg-SRLs were switched to alternative 
treatment options, if available, and did not reach the 
6  months follow-up period required for admission in 
the study. However, before considering fg-SRL resist-
ance, at least 6 months are generally assumed to be ne-
cessary to assess treatment outcome (19, 45). Finally, we 
are limited by the use of different IGF-1 assays during 
fg-SRL treatment.
SRLs remain the mainstay of medical therapy in 
acromegaly; however, a proportion of patients are at 
least partially resistant to treatment. Patient-specific 
clinical predictors of fg-SRL response in patients 
with acromegaly include baseline IGF-1 concentra-
tion as the best predictor: lower baseline IGF-1 con-
centrations could identify patients that will achieve 
biochemical control, while higher baseline IGF-1 
concentrations could identify those that will achieve 
partial responses while at the same time having a 
greater absolute and relative reduction in circulating 
IGF-1 levels. In the latter group, a greater reduction 
in IGF-1 levels even it does not decrease below the set 
threshold is still of great clinical value in the multi-
modal therapy setting. Other patient-specific clinical 
predictors of fg-SRL response are bodyweight, the 
presence of type 2 DM, age at diagnosis and a trend 
towards tumor size and previous surgery. These pre-
diction models can be used to guide and individualize 
treatments and could avoid the negative consequences 
of ineffective treatment with fg-SRLs such as pro-
longed active biochemical and metabolic disease.
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